Novo Nordisk Discloses Insider Share Transactions
Ticker: NONOF · Form: 6-K · Filed: Aug 14, 2025 · CIK: 353278
Sentiment: neutral
Topics: insider-trading, disclosure, regulation
Related Tickers: NVO
TL;DR
Novo Nordisk insiders bought/sold shares, check the filing for details.
AI Summary
Novo Nordisk A/S announced on August 12, 2025, that it is disclosing transactions in its shares made by board members, executives, and associated persons. This disclosure is in accordance with Article 19 of Regulation No. 596/2014 on market abuse.
Why It Matters
This filing provides transparency into the trading activities of company insiders, which can offer insights into their confidence in the company's future performance.
Risk Assessment
Risk Level: low — The filing is a routine disclosure of insider trading activity and does not present new financial or operational risks.
Key Players & Entities
- Novo Nordisk A/S (company) — Registrant
- August 12, 2025 (date) — Announcement Date
- Regulation No. 596/2014 (regulation) — Governing regulation for disclosure
- Article 19 (regulation) — Specific article requiring disclosure
FAQ
What is the purpose of this Form 6-K filing?
The purpose is to disclose transactions in Novo Nordisk shares made by the company's board members, executives, and their associated persons, in accordance with market abuse regulations.
When was this company announcement made?
The company announcement was made on August 12, 2025.
Which regulation governs these disclosures?
These disclosures are made in accordance with Article 19 of Regulation No. 596/2014 on market abuse.
Who is required to report their transactions?
Board members, executives, and their associated persons of Novo Nordisk are required to report their transactions in Novo Nordisk shares.
Where is Novo Nordisk A/S headquartered?
Novo Nordisk A/S is headquartered in Bagsvaerd, Denmark.
Filing Stats: 507 words · 2 min read · ~2 pages · Grade level 12.9 · Accepted 2025-08-14 06:00:12
Filing Documents
- f6k_081225.htm (6-K) — 25KB
- logo.jpg (GRAPHIC) — 76KB
- ca.jpg (GRAPHIC) — 24KB
- 0001171843-25-005391.txt ( ) — 164KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf of the undersigned, thereunto duly authorized. Date: August 12, 2025 NOVO NORDISK A/S Maziar Mike Doustdar Chief Executive Officer